Brainsway

Brainsway Ltd. is a commercial stage medical device company, which focuses on the development and sale of non-invasive neuromodulation products using the proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) technology for the treatment of major depressive disorder (MDD) and obsessive-compulsive disorder (OCD). The Deep TMS uses magnetic pulses to stimulate neurons and consequently modulates the physiological activity of the brain. The company was founded by Avner Hagai, Yiftach Roth, Abraham Zangen, and David Zacut on November 7, 2006 and is headquartered in Jerusalem, Israel.

Earnings data Q3 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Brainsway Ltd. engages in the development and sale of non-invasive neurostimulation treatments using the proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) technology for the treatment of major depressive disorder (MDD) and obsessive-compulsive disorder (OCD). The Deep TMS uses magnetic pulses to stimulate neurons and consequently modulates the physiological activity of the brain. The company was founded by Avner Hagai, Yiftach Roth, Abraham Zangen, and David Zacut on November 7, 2006 and is headquartered in Jerusalem, Israel.

CRESSKILL, N.J. and JERUSALEM, Israel, Aug.  12, 2020  (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in the advanced non-invasive treatment of brain disorders, today reported financial results for the quarter ended June 30, 2020, and provided an operational update.

BrainsWay Reports Second Quarter 2020 Financial Results and Operational Highlights

CRESSKILL, N.J. and JERUSALEM, Israel, July  29, 2020  (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in the advanced noninvasive treatment of brain disorders, today announced that it will report its second quarter 2020 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, August 12, 2020. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.

BrainsWay to Report Second Quarter 2020 Financial Results and Operational Highlights on August 12, 2020

PATTERSON, N.J., July  21, 2020  (GLOBE NEWSWIRE) --  BrainsWay  Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in the advanced noninvasive treatment of brain disorders, today announced the Company will participate in the upcoming mental health conferences:

BrainsWay to Participate in Virtual Conferences Elevate by Psych Congress Virtual Experience and Online Obsessive-Compulsive Disorder (OCD) in July 2020

BrainsWay Ltd. (BWAY) CEO Christopher von Jako on Q1 2020 Results - Earnings Call Transcript

PATTERSON, N.J. and JERUSALEM, June  24, 2020  (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today, June 24th, by BrainsWay Ltd. (NASDAQ & TASE: BWAY), please note that, in the first table, CONSOLIDATED STATEMENTS OF FINANCIAL POSITION, line item five under CURRENT ASSETS should read "24,735" instead of "4,735." The corrected release follows:

CORRECTION - BrainsWay Reports First Quarter 2020 Financial Results and Operational Highlights

PATTERSON, N.J. and JERUSALEM, June  24, 2020  (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in the advanced non-invasive treatment of brain disorders, today reported financial results for the quarter ended March 31, 2020, and provided an operational update.

BrainsWay Reports First Quarter 2020 Financial Results and Operational Highlights

New site features user-friendly layout, easy access to resources, and tools for those affected by COVID-19 New site features user-friendly layout, easy access to resources, and tools for those affected by COVID-19

BrainsWay Launches New Website to Enhance Mental Health Awareness

PATTERSON, N.J., May  20, 2020  (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in the advanced non-invasive treatment of brain disorders, today announced the appointment of Christopher Boyer as Vice President of Global Marketing.  Mr. Boyer will be responsible for worldwide marketing activities with a focus on expanding BrainsWay’s market share, leading the corporate go-to-market strategy, and overseeing the continued development of the BrainsWay brand.  He has more than 15 years of medical device marketing and business development experience in both privately-held and multi-billion dollar publicly-held medical device companies.

BrainsWay Strengthens Senior Leadership Team with Appointment of Christopher Boyer as Vice President of Global Marketing

Hadar Levy Promoted to Senior Vice President and General Manager of North America

BrainsWay Enhances Senior Leadership with Promotion and New Executive Addition

BrainsWay will donate $1 per entry to the National Alliance of Mental Illness (NAMI) and each entry will be entered for a chance to win a $250 Amazon gift card BrainsWay will donate $1 per entry to the National Alliance of Mental Illness (NAMI) and each entry will be entered for a chance to win a $250 Amazon gift card

BrainsWay Launches #StandAgainstTheStigma Campaign to Promote Mental Health Awareness Month

PATTERSON, N.J., April  13, 2020  (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in the advanced non-invasive treatment of brain disorders, today announced a preliminary, unaudited revenue range for the first quarter ended March 31, 2020. Specifically, the Company expects first quarter revenues to be within the range of $3.9 million to $4.2 million.

BrainsWay Announces Preliminary Revenue Range for First Quarter of 2020

Brainsway Continues Growth Trajectory While Conserving Cash

Brainsway Ltd. (BWAY) CEO Christopher von Jako on Q4 2019 Results - Earnings Call Transcript

Results demonstrate increased activity in attention-related brain networks treated with BrainsWay’s H6-coil, which correlate with observed improvement in ADHD symptoms

BrainsWay Announces Data from Feasibility Study of Deep Transcranial Magnetic Stimulation System in the treatment of Adults with ADHD

Lushi also to serve on Company’s audit committee Lushi also to serve on Company’s audit committee

BrainsWay Appoints Avner Lushi to Join Board of Directors

Company to discontinue funding of study following insufficient demonstration of efficacy Company to discontinue funding of study following insufficient demonstration of efficacy

BrainsWay Reports Results of Interim Analysis of H7 Deep Transcranial Magnetic Stimulation Study in Post-Traumatic Stress Disorder

Shares of Brainsway  are up 10% in premarket trading on positive trial results for its brain stimulation device as a smoking cessation tool for longtime chronic cigarette smokers.

Brainsway shares up on smoking cessation data

Primary and secondary endpoint achieved with statistical significance

BrainsWay Announces Successful Results in Pivotal Multicenter Study Evaluating Deep Transcranial Magnetic Stimulation System as an Aid in Smoking Cessation

Brainsway Ltd. (BWAY) CEO David Zacut on Q3 2019 Results - Earnings Call Transcript

JERUSALEM and HACKENSACK, N.J., Nov.  25, 2019  (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) and its subsidiary BrainsWay USA, Inc., a global leader in the advanced non-invasive treatment of brain disorders, today announced that its Board of Directors has decided to appoint Christopher von Jako, Ph.D., as President and Chief Executive Officer (CEO). Dr. von Jako’s appointment cements the Board's commitment to a strategic transition to U.S.-based leadership, and will become effective in January 2020.

BrainsWay Appoints Medical Technology Industry Leader Christopher R. von Jako, Ph.D.

JERUSALEM, Nov.  25, 2019  (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ: BWAY, TASE: BWAY), a global leader in the advanced non-invasive treatment of brain disorders, announced today that it will be exhibiting its new state-of-the-art deep transcranial magnetic stimulation (dTMS) platform for the first time in Germany, at the 2019 German Association for Psychiatry, Psychotherapy and Psychosomatics (DGPPN) Congress scheduled to take place in Berlin from November 27-30, 2019. The platform includes the company’s new proprietary stimulator and is designed to treat a variety of neuropsychiatric conditions, including Major Depressive Disorder (MDD) and Obsessive-Compulsive Disorder (OCD).

BrainsWay‘s New Stimulator for Deep Transcranial Magnetic Stimulation Makes German Debut at the 2019 German Association for Psychiatry, Psychotherapy and Psychosomatics Congress

Deep Transcranial Magnetic Stimulation (Deep TMS) helmet approved to treat MDD is now available in Greenwood Village Deep Transcranial Magnetic Stimulation (Deep TMS) helmet approved to treat MDD is now available in Greenwood Village

A Stepping Stone Hosts Open House to Introduce Newly Offered FDA-Cleared Helmet to Treat Major Depressive Disorder (MDD)

BrainsWay is a technology leader in the transcranial magnetic stimulation market which holds significant potential if it becomes widely accepted by doctors and patients.

News for Brainsway Stock (BWAY)